Table 2.
Variations in IL-36α levels within the BS cohort, according to manifestations in the whole medical history, presence of HLA-B51, active disease at time of enrolment and pharmacological therapies.
| With the Considered Feature |
Without the Considered Feature |
p-Value # | |
|---|---|---|---|
| IL-36 (pg/mL) | IL-36 (pg/mL) | ||
| Overall | 201.7 (112.7–320.2) | ||
| Disease manifestations | |||
| Genital aphthosis | 269.4 (173.2–384.5) | 176.1 (109.2–266.3) | 0.015 * |
| Cutaneous | 207.2 (132.9–323.4) | 192.2 (94.9–271.2) | 0.284 |
| Arthritis | 201.7 (120.2–320.2) | 194.2 (104.8–344.2) | 0.784 |
| Intestinal symptoms | 212.2 (104.8–360.4) | 200.2 (118.2–316.5) | 0.950 |
| Uveitis | 243.4 (192.2–345.1) | 173.2 (94.9–312.3) | 0.029 * |
| Vascular | 269.4 (208.2–351.4) | 192.2 (108.1–296.2) | 0.072 |
| Neurological | 228.3 (171.1–375.2) | 194.3 (108.1–318.3) | 0.240 |
| HLA-B51 | 229.7 (152.0–340.8) | 193.2 (94.9–312.3) | 0.237 |
| Active disease | 200.7 (106.5–379.9) | 201.7 (133.0–296.2) | 0.529 |
| BDCAF | Spearman’s rho: 0.492 | <0.001 * | |
| Ongoing immunomodulating treatment | |||
| Corticosteroids/colchicine | 245.7 (160.5–348.3) | 0.138 | |
| csDMARDs | 192.2 (120.2–252.2) | ||
| Biologic (±cs) DMARDs | 176.1 (82.9–294.4) | ||
# p-value from Mann-Whitney or Krusal–Wallis test for unpaired data, comparing IL-36α levels in patients with vs without a considered feature. * Statistically significant with p-value < 0.05. BDCAF: Behçet’s Disease Current Activity Form; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; HLA: human leukocyte antigen.